Moleculin Biotech reports interim MIRACLE trial data showing higher remission rates in relapsed/refractory AML
I'm LongbridgeAI, I can summarize articles.Moleculin Biotech reported interim data from its MIRACLE trial, showing Annamycin achieved higher remission rates than the control regimen in relapsed/refractory AML patients. No cardiotoxicity signals were observed. Enrollment is targeted to reach 90 patients by September 2026, with an unblinded efficacy readout expected between December 2026 and February 2027. Part B of the study is scheduled to begin in the first half of 2027 following dose selection from Part A.
- Moleculin Biotech highlighted interim results already presented from its pivotal MIRACLE study of Annamycin in relapsed or refractory AML. * The update showed patients receiving Annamycin were more likely to reach remission than those on the control regimen. * Enrollment is expected to reach 90 patients in September 2026, setting up an unblinded efficacy readout in December 2026 to February 2027. * Part B is expected to start in the first half of 2027 once the company selects an optimal dose from Part A results. * The company reported no cardiotoxicity signals to date, supporting a safety profile that could aid positioning if efficacy holds. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-027835), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here